Use of vivo-morpholinos for control of protein expression in the adult rat brain

Journal of Neuroscience Methods

Volumn 203, Issue 2, 2012, Pages 354-360

  Reissner, Kathryn J ^a   Sartor, Gregory C ^a   Vazey, Elena M ^a   Dunn, Thomas E ^a   Aston Jones, Gary ^a   Kalivas, Peter W ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antisense; GLT 1; Hypocretin; Lateral hypothalamus; Nucleus accumbens; Orexin; Vivo morpholino; XCT

Indexed keywords

CYSTEINE GLUTAMATE EXCHANGER TRANSPORTER; GLUTAMATE TRANSPORTER; MORPHOLINE DERIVATIVE; OREXIN; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1; VIVO MORPHOLINO;

ANIMAL EXPERIMENT; ANTISENSE THERAPY; ARTICLE; BEHAVIOR; BRAIN; BRAIN FUNCTION; BRAIN REGION; CONTROLLED STUDY; GENE REPRESSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MICROINJECTION; NERVOUS SYSTEM; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAT;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); BRAIN; MALE; MICROINJECTIONS; MORPHOLINOS; NERVE TISSUE PROTEINS; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 82055165305     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2011.10.009     Document Type: Article

References (39)

1. Aitman T.J., Critser J.K., Cuppen E., Dominiczak A., Fernandez-Suarez X.M., Flint J., et al. Progress and prospects in rat genetics: a community view. Nat Genet 2008, 40:516-522.
2. Albrecht P., Lewerenz J., Dittmer S., Noack R., Maher P., Methner A. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target. CNS Neurol Disord Drug Targets 2010, 9:373-382.
3. Alter J., Lou F., Rabinowitz A., Yin H., Rosenfeld J., Wilton S.D., et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006, 12:175-177.
4. Aston-Jones G., Smith R.J., Sartor G.C., Moorman D.E., Massi L., Tahsili-Fahadan P., et al. Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Res 2010, 1314:74-90.
5. Berridge K.C., Ho C.Y., Richard J.M., DiFeliceantonio A.G. The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res 2010, 1350:43-64.
6. Cason A.M., Smith R.J., Tahsili-Fahadan P., Moorman D.E., Sartor G.C., Aston-Jones G. Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Physiol Behav 2010, 100:419-428.
7. Chen L., Thakkar M.M., Winston S., Bolortuya Y., Basheer R., McCarley R.W. REM sleep changes in rats induced by siRNA-mediated orexin knockdown. Eur J Neurosci 2006, 24:2039-2048.
8. Corey D.R., Abrams J.M. Morpholino antisense oligonucleotides: tools for investigating vertebrate development. Genome Biol 2001, 2. Reviews 1015.
9. Fletcher S., Honeyman K., Fall A.M., Harding P.L., Johnsen R.D., Steinhaus J.P., et al. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007, 15:1587-1592.
10. Hartwig S., Ho J., Pandey P., Macisaac K., Taglienti M., Xiang M., et al. Genomic characterization of Wilms' tumor suppressor 1 targets in nephron progenitor cells during kidney development. Development 2010, 137:1189-1203.
11. Heasman J. Morpholino oligos: making sense of antisense?. Dev Biol 2002, 243:209-214.
12. Hiroi R., McDevitt R.A., Morcos P.A., Clark M.S., Neumaier J.F. Overexpression or knockdown of rat tryptophan hyroxylase-2 has opposing effects on anxiety behavior in an estrogen-dependent manner. Neuroscience 2011, 176:120-131.
13. Jearawiriyapaisarn N., Moulton H.M., Buckley B., Roberts J., Sazani P., Fucharoen S., et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008, 16:1624-1629.
14. Jones S.W., Christison R., Bundell K., Voyce C.J., Brockbank S.M., Newham P., et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol 2005, 145:1093-1102.
15. Knackstedt L.A., Melendez R.I., Kalivas P.W. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry 2010, 67:81-84.
16. Levivier M., Gash D.M., Przedborski S. Time course of the neuroprotective effect of transplantation on quinolinic acid-induced lesions of the striatum. Neuroscience 1995, 69:43-50.
17. Li Y.F., Morcos P.A. Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo. Bioconjug Chem 2008, 19:1464-1470.
18. Maragakis N.J., Rothstein J.D. Glutamate transporters: animal models to neurologic disease. Neurobiol Dis 2004, 15:461-473.
19. Morcos P.A., Li Y., Jiang S. Vivo-morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques 2008, 45:613-614. 616, 618 passim.
20. Morris K.V. RNA-mediated transcriptional gene silencing in human cells. Curr Top Microbiol Immunol 2008, 320:211-224.
21. Moulton J.D., Jiang S. Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules 2009, 14:1304-1323.
22. Moulton J.D., Yan Y.L. Using Morpholinos to control gene expression. Curr Protoc Mol Biol 2008, 26. [chapter 26: Unit 26 8].
23. Mullen R.J., Buck C.R., Smith A.M. NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992, 116:201-211.
24. Oh I.S., Shimizu H., Satoh T., Okada S., Adachi S., Inoue K., et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006, 443:709-712.
25. Parra M.K., Gee S., Mohandas N., Conboy J.G. Efficient in vivo manipulation of alternative pre-mRNA splicing events using antisense morpholinos in mice. J Biol Chem 2011, 286:6033-6039.
26. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Elsevier Academic, Amsterdam. 5th ed.
27. Reissner K.J., Kalivas P.W. Using glutamate homeostasis as a target for treating addictive disorders. Behav Pharmacol 2010, 21:514-522.
28. Self D.W. Molecular and genetic approaches for behavioral analysis of protein function. Biol Psychiatry 2005, 57:1479-1484.
29. Sharp P.S., Bye-a-Jee H., Wells D.J. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther 2011, 19:165-171.
30. Sheldon A.L., Robinson M.B. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 2007, 51:333-355.
31. Shih A.Y., Erb H., Sun X., Toda S., Kalivas P.W., Murphy T.H. Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. J Neurosci 2006, 26:10514-10523.
32. Summerton J.E. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem 2007, 7:651-660.
33. Tanaka K., Watase K., Manabe T., Yamada K., Watanabe M., Takahashi K., et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997, 276:1699-1702.
34. Tesson L., Cozzi J., Menoret S., Remy S., Usal C., Fraichard A., et al. Transgenic modifications of the rat genome. Transgenic Res 2005, 14:531-546.
35. Thompson J.L., Borgland S.L. A role for hypocretin/orexin in motivation. Behav Brain Res 2011, 217:446-453.
36. Toda S., Shen H.W., Peters J., Cagle S., Kalivas P.W. Cocaine increases actin cycling: effects in the reinstatement model of drug seeking. J Neurosci 2006, 26:1579-1587.
37. Valentine G.W., Sanacora G. Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol 2009, 78:431-439.
38. Wadia J.S., Dowdy S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005, 57:579-596.
39. Zaczek R., Simonton S., Coyle J.T. Local and distant neuronal degeneration following intrastriatal injection of kainic acid. J Neuropathol Exp Neurol 1980, 39:245-264.